Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Companies Wary Of CMS Plans For Cost-Effectiveness Research

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS Administrator nominee McClellan is expected to "pick up and continue" where former Administrator Scully left off in controlling drug prices, Ligand marketing exec Erwin says at BIO conference.

You may also be interested in...



Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling

The “Archimedes” trial results simulator would allow third-party payors to predict the amount of time before a new drug saves money. Kaiser is spending $17 mil. to develop the model, which could be available at a “non-profit” cost in three years.

Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling

The “Archimedes” trial results simulator would allow third-party payors to predict the amount of time before a new drug saves money. Kaiser is spending $17 mil. to develop the model, which could be available at a “non-profit” cost in three years.

McClellan To Head Medicare Rx Law Implementation: Will Greater FDA/CMS Cooperation Ensue?

President Bush nominates FDA Commissioner McClellan to head Centers for Medicare & Medicaid Services Feb. 20. McClellan's closest advisors will remain at FDA, suggesting era of greater cooperation between the two agencies could result.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel